- WIBP to implement ProMetic's yield improving technologies for new
generation of plasma-derived products
- Agreement targets commercial scale at (greater than) 1.2 million Litres
of plasma annually
- China expected to become world's 4th largest domestic pharmaceutical
market by 2012
WUHAN, BEIJING, CHINA, AND MONTREAL, March 12 /CNW Telbec/ - Wuhan
Institute of Biological Products, ("WIBP") a subsidiary of China National
Biotec Group ("CNBG") and ProMetic Life Sciences Inc. (TSX:PLI) ("ProMetic")
announced today that they have signed a strategic alliance and license
agreement. Under the terms of this agreement, WIBP gains exclusive access to
ProMetic's Plasma Protein Purification System ('PPPS") for the Chinese market.
Upon successfully implementing this technology, WIBP will be able to
significantly improve its capability in the manufacturing of plasma-derived
products in China.
ProMetic will assist WIBP to implement a product development program that
is being initiated immediately, which includes training, technology transfer,
and scale up, as well as readiness of the clinical manufacturing facility.
WIBP will take the lead in conducting the clinical trials to obtain required
regulatory approval by the Chinese State Food and Drug Administration
("SFDA"). Full scale commercial manufacturing will take place at WIBP
initially, could be readily implemented by other affiliated companies within
CNBG later, with the goal to achieve a minimum capacity greater than
1.2 million L plasma per year.
"The integration of ProMetic's technologies into WIBP's existing
manufacturing infrastructure will significantly increase WIBP's manufacturing
capacity and enable WIBP to better meet the ever growing demand in China,"
stated Ms. Lifang Wang, President & Chief Executive Officer of CNBG.
"This agreement leverages each company's expertise and is expected to
build value while bringing a new generation of plasma-derived products to the
Chinese market," explained Mr. Gungrong Zhou, Director of WIBP. "The company
will utilize ProMetic's new manufacturing technology to improve the quality of
the current products as well as to introduce new products to meet the medical
"WIBP's proven track record in the development and marketing of
plasma-derived products in China is strategic for ProMetic," commented Mr.
Pierre Laurin, President and Chief Executive Officer of ProMetic. "With its
rapid economic growth, China is poised to become the world's fourth largest
domestic market for pharmaceuticals."
The products being targeted initially will include thrombin, fibrinogen,
albumin, intravenous immunoglobulin, Alph-1 protease inhibitor and multiple
hyperimmunoglobulins such as anti-hepatitis B immunoglobulin, anti-rabies
immunoglobulin, anti-tetanus immunoglobulin. These products are expected to
start reaching commercial stage by 2012 / 2013. Additional products will be
"We are very please to introduce this manufacturing platform to WIBP,
which in addition to provide significant yield improvement over the current
technology, also allows for additional products to be recovered from plasma,"
commented Dr. Tom Chen, Vice-President, Process Development of ProMetic
"With advantages of higher yield and more products produced from each
unit of plasma collected, this technology provides us with an ideal solution
to best utilize the precious raw material- plasma, currently in short supply,
as well as broaden our product portfolio to better serve medical needs in
China. We are very exciting to work with ProMetic in implementing this
promising manufacturing technology," commented Dr. Xiaoming Yang, Deputy
Director who is in charge of R&D and Sales & Marketing in WIBP.
More about Wuhan Institute of Biological Products
Wuhan Institute of Biological Products ("WIBP") (www.wibp.com.cn),
located in Wuhan, China. is one of the subsidiaries of CNBG, has over 50 years
experience in the fields of biomedical research and product development;
historically strong in R&D, WIBP is the only institute certified by state to
offer doctoral program among six Institute of Biological Products in CNBG.
Today, WIBP has more than 1,000 employees, and major products include two
dozen vaccines and plasma derivatives currently marketed throughout the China.
More about China National Biotec Group
China National Biotec Group (CNBG) (www.cnbgint.com or www.cnbg.com.cn),
headquartered in Beijing, China , is a state-owned enterprise and the largest
biotech company in China dedicated to discover, develop, manufacture and
market a broad range of human health products, including vaccines, blood
derivatives, biopharmaceuticals, diagnostic reagents and others. With more
than 9,000 employees and revenues of 421 million USD in 2006, CNBG is the
largest producer of vaccines and blood derivatives in China, enjoying more
than 80% and 30% market share respectively. The company consists of
6 Institute of Biological Products and an international trading company.
About ProMetic Life Sciences Inc.
ProMetic Life Sciences Inc. ("ProMetic") (www.prometic.com) is a
biopharmaceutical company specialized in the research, development,
manufacture and marketing of a variety of commercial applications derived from
its proprietary Mimetic Ligand(TM) technology. This technology is used in
large-scale purification of biologics and the elimination of pathogens.
ProMetic is also active in therapeutic drug development with the mission to
bring to market effective, innovative, lower cost, less toxic products for the
treatment of hematology and cancer. Its drug discovery platform is focused on
replacing complex, expensive proteins with synthetic "drug-like" protein
mimetics. Headquartered in Montréal (Canada), ProMetic has R&D facilities in
the U.K., the U.S. and Canada, manufacturing facilities in the U.K. and
business development activities in the U.S., Europe, Asia and in the
About ProMetic BioTherapeutics, Inc.
ProMetic BioTherapeutics, Inc. ("PBT") is the world leader in plasma
protein fractionation technology. Headquartered in Rockville, MD (U.S.), PBT
is proprietor of a unique, proven, state-of-the-art solution for plasma
fractionation Plasma Protein Purification System ("PPPS"). The advantages of
PBT's protein extraction technology are being increasingly recognized
About ProMetic BioSciences Ltd
Using its unique and proprietary Mimetic Ligand(TM) technology, ProMetic
BioSciences Ltd ("PBL") specializes in the development and manufacture of
robust affinity separation materials which provide very high levels of
purification. This is achieved by use of small chemical affinity ligands
designed to bind a target biomolecule specifically and reversibly. In view of
their use for the production of therapeutics, ProMetic's affinity products are
manufactured according to a strict quality system based on good manufacturing
practice at PBL's ISO 9001:2000 certified manufacturing facility on the Isle
of Man, which completed a (pnds stlg)1.5 million expansion in 2005. PBL also
operates an R&D laboratory located on the Cambridge Science Park,
Forward Looking Statements
This document contains forward-looking statements about ProMetic's
objectives, strategies and businesses that involve risks and uncertainties.
These statements are "forward-looking" because they are based on our current
expectations about the markets we operate in and on various estimates and
assumptions. Actual events or results may differ materially from those
anticipated in these forward-looking statements if known or unknown risks
affect our business, or if our estimates or assumptions turn out to be
inaccurate. Such risks and assumptions include, but are not limited to,
ProMetic's ability to develop, manufacture, and successfully commercialize
value-added pharmaceutical products, the availability of funds and resources
to pursue R&D projects, the successful and timely completion of clinical
studies, the ability of ProMetic to take advantage of business opportunities
in the pharmaceutical industry, uncertainties related to the regulatory
process and general changes in economic conditions. You will find a more
detailed assessment of the risks that could cause actual events or results to
materially differ from our current expectations on page 21 of ProMetic's
Annual Information Form for the year ended December 31, 2006, under the
heading "Risk Factors". As a result, we cannot guarantee that any
forward-looking statement will materialize. We assume no obligation to update
any forward-looking statement even if new information becomes available, as a
result of future events or for any other reason, unless required by applicable
securities laws and regulations.
For further information:
For further information: Company Inquiries: Pierre Laurin, President and
CEO, ProMetic Life Sciences Inc., email@example.com, (514) 341-2115;
Dominic Sicotte, Echoes Financial Network Inc., firstname.lastname@example.org,
(514) 842-9551; Anne Leduc, Manager, Investor Relations & Communications,
ProMetic Life Sciences Inc., email@example.com, (514) 341-2115; Investor
Relations: Bruce Voss, Lippert/Heilshorn & Associates, BVoss@lhai.com, (310)
691-7100; Kim Golodetz, Lippert/Heilshorn & Associates, KGolodetz@lhai.com,
(212) 838-3777; Media Relations: Jules Abraham, Lippert/Heilshorn &
Associates, JAbraham@lhai.com, (212) 838-3777